BioSpace News Archive

Medison Pharma is pleased to announce the approval of KIMMTRAK® by Health Canada and Therapeutics Goods Administration for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the eye.

Amaroq Therapeutics is progressing towards clinical trials following a promising initial development phase and securing key appointments to its Scientific Advisory Board.

icometrix announced that DocPanel has selected the icobrain portfolio to strengthen its AI imaging capability and transform the market for people with traumatic brain injury.

Typenex® Medical LLC, a pioneer in patient identification solutions, has been awarded a three-year group purchasing contract with Premier, Inc., a leading healthcare improvement company.

Element Biosciences, Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, announced it has shipped multiple AVITI systems to its first set of customers.

Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced it will host a panel discussion with leading neurology experts on Tuesday, June 14th at 5:00 p.m. ET.

Gritstone bio, Inc. announced that the company’s Board of Directors has granted eighteen employees nonqualified stock options to purchase an aggregate of 206,550 shares of its common stock with an exercise price of $1.85, which is equal to the closing price of Gritstone’s common stock on May 27, 2022, the grant date of the awards.

HTG Molecular Diagnostics, Inc. announced that it will be sponsoring a keynote presentation at the 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference in San Diego, CA, titled “Implementing Biomarker Strategy in Clinical Trials” on June 16th at 9:05 AM PT.

Tonix Pharmaceuticals Holding Corp. announced that Tom Hobman, Ph.D., Professor, Department of Cell Biology, University of Alberta, presented data from his laboratory at The University of Alberta as a keynote presentation at the 4th Symposium of the Canadian Society for Virology held in Edmonton, Alberta, Canada on June 5, 2022.

MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the Company’s management will participate in the following investor conference in June 2022.